ESR1 and cancer: According to the analyzing result of 123,780 cases of stage 1-3 primary female invasive breast cancer from the California Cancer Registry, HER-2 overexpressing (ER−/PR−/HER-2+) and triple negative (ER−/PR−/HER-2−) had poorer prognosis than other subtypes.